By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Low-risk MDS had many exciting updates, starting with the COMMANDS trial. This study is an open-label randomized phase 3 trial
By Dr. Harsh Parmar Hackensack Meridian Health In an unplanned interim analysis of an international phase-III trial (ATLAS) by Dytfeld et al., performed across 12 centers in Poland and the US,
More
By Dr. Abhishek A. Mangaonkar Mayo Clinic The phase 2 FIGHT-203 trial (NCT#03011372) studied 28 patients with relapsed/refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. FGFR1 rearrangement should be suspected in patients who
More
Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Philadelphia positive acute lymphoblastic leukemia treatment has been driven by the combination of tyrosine kinase inhibitors targeting BCR-ABL in conjunction with
More
Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic In the phase III AGILE trial reported in the New England Journal of Medicine, Pau
More
By Luke Fletcher, MD Willamette Valley Cancer Institute & Research Center Imetelstat, a telomerase inhibitor, has shown interesting promise for ESA refractory or unlikely to respond low-risk Myelodysplastic syndrome (MDS). In
More
The Binaytara Foundation organized three in-person oncology conferences in October 2021. The 2021 Updates in Hematologic Malignancies and the 2021 Precision Oncology Summit were held in Salt Lake City, Utah on October
More